Insider Trading Alert - CTSH, VNTV And JAZZ Traded By Insiders
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.
Friday, March 20, 2015, 84 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $473.57 to $48,050,000.00.
Highlighted Stocks Traded by Insiders:
Cognizant Technology Solutions (CTSH) - FREE Research Report
McLoughlin Karen, who is Chief Financial Officer at Cognizant Technology Solutions, sold 1,863 shares at $62.78 on March 20, 2015. Following this transaction, the Chief Financial Officer owned 25,442 shares meaning that the stake was reduced by 6.82% with the 1,863-share transaction.
The shares most recently traded at $63.89, up $1.11, or 1.74% since the insider transaction. Historical insider transactions for Cognizant Technology Solutions go as follows:
- 4-Week # shares sold: 2,210
- 12-Week # shares sold: 354,252
- 24-Week # shares bought: 7,500
- 24-Week # shares sold: 458,813
The average volume for Cognizant Technology Solutions has been 3.9 million shares per day over the past 30 days. Cognizant Technology Solutions has a market cap of $39.2 billion and is part of the technology sector and computer software & services industry. Shares are up 21.65% year-to-date as of the close of trading on Friday.
Cognizant Technology Solutions Corporation provides information technology (IT), consulting, and business process services worldwide. The company operates through four segments: Financial Services, Healthcare, Manufacturing/Retail/Logistics, and Other. The company has a P/E ratio of 27.3. Currently, there are 16 analysts who rate Cognizant Technology Solutions a buy, no analysts rate it a sell, and 2 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on CTSH - FREE
rates Cognizant Technology Solutions as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, increase in net income and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full
Cognizant Technology Solutions Ratings Report
from
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Vantiv (VNTV) - FREE Research Report
Drucker Charles, who is President & CEO at Vantiv, sold 100,000 shares at $38.60 on March 20, 2015. Following this transaction, the President & CEO owned 837,256 shares meaning that the stake was reduced by 10.67% with the 100,000-share transaction.
The shares most recently traded at $38.68, up $0.08, or 0.21% since the insider transaction. Historical insider transactions for Vantiv go as follows:
- 4-Week # shares sold: 12,000
- 12-Week # shares sold: 65,356
- 24-Week # shares sold: 124,057
The average volume for Vantiv has been 1.1 million shares per day over the past 30 days. Vantiv has a market cap of $5.7 billion and is part of the services sector and diversified services industry. Shares are up 14.92% year-to-date as of the close of trading on Friday.
Vantiv, Inc., through its subsidiary, Vantiv Holding, LLC. provides payment processing services in the United States. It operates through two segments, Merchant Services and Financial Institution Services. The company has a P/E ratio of 51.9. Currently, there are 14 analysts who rate Vantiv a buy, no analysts rate it a sell, and 5 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on VNTV - FREE
rates Vantiv as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income, expanding profit margins, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full
from
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Jazz Pharmaceuticals (JAZZ) - FREE Research Report
Mulligan Seamus, who is Director at Jazz Pharmaceuticals, sold 50,000 shares at $185.00 on March 20, 2015. Following this transaction, the Director owned 1.2 million shares meaning that the stake was reduced by 3.98% with the 50,000-share transaction.
The shares most recently traded at $184.60, down $0.40, or 0.22% since the insider transaction. Historical insider transactions for Jazz Pharmaceuticals go as follows:
- 4-Week # shares sold: 5,500
- 12-Week # shares sold: 15,500
- 24-Week # shares sold: 94,312
The average volume for Jazz Pharmaceuticals has been 647,400 shares per day over the past 30 days. Jazz Pharmaceuticals has a market cap of $11.4 billion and is part of the health care sector and drugs industry. Shares are up 15.44% year-to-date as of the close of trading on Friday.
Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a P/E ratio of 201.2. Currently, there are 11 analysts who rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on JAZZ - FREE
rates Jazz Pharmaceuticals as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full
Jazz Pharmaceuticals Ratings Report
from
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
null